Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. is trading at $26.46, up 1.57% on the session. The 50 day average sits at $26.41 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 39.5, which reads as weak, and MACD is bearish crossover. Volume is average.

The nearest support is around $24.95 with resistance near $28.09, so that band frames the current range. Average daily movement is roughly $1.23, or about 4.7% of the share price, which is what any stop placement has to allow for. The overall health score of 43 out of 100 combines a trend score of 44, momentum of 28 and a risk score of 63.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.